Geron Corporation (GERN): A Tribute to Alex Barkas
11/23/2011 10:06:47 AM
More...
|
Baxter International, Inc. (BAX) Announces Acquisition of All Hemophilia-Related Assets of Archemix Corporation and an Exclusive License of Its Anti-TFPI Aptamer Technology for $30 Million Upfront Plus Possible $285 Million More in Milestones
11/19/2010 7:47:11 AM
More...
|
miRagen Therapeutics and Archemix Corporation to Collaborate on Conjugated Aptamer-microRNA Therapeutics
7/23/2009 9:29:23 AM
More...
|
Archemix Corporation and Dicerna Pharmaceuticals to Collaborate on Conjugated Aptamer-Dicer Substrate RNAi Therapeutics
7/21/2009 6:53:02 AM
More...
|
Archemix Corporation Appoints Ken Bate as President and Chief Executive Officer
5/6/2009 7:07:25 AM
More...
|
Archemix Corporation Initiates Phase 2a for Lead Aptamer Product Candidate ARC1779
3/30/2009 8:47:03 AM
More...
|
Archemix Corporation Merger with NitroMed, Inc. (NTMD) Falls Through
1/28/2009 8:29:08 AM
More...
|
Archemix Corporation Announces Continued Progress with Business Strategy
1/27/2009 2:20:04 PM
More...
|
GlaxoSmithKline (GSK) (JOBS) and Archemix Corporation Form Strategic Alliance Worth $1.4 Billion to Develop Aptamers to Treat Inflammatory Diseases
12/23/2008 6:50:27 AM
More...
|
Archemix Corporation Announces ARC1779 Data to Be Presented at Upcoming American Society of Hematology Annual Meeting, December 6-9, 2008
12/4/2008 9:17:14 AM
More...
|
|